Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome

Signal Transduction and Targeted Therapy

Volumn 4, Issue 1, 2019, Pages

  Zhang, Ziying ^a,b,c   Tang, Haosheng ^a,b,c   Chen, Peng ^c   Xie, Hui ^d   Tao, Yongguang ^a,b,c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; GASTROINTESTINAL TRACT; IMMUNE RESPONSE; MASS SPECTROMETRY; METABOLISM; MICROBIOME; NONHUMAN; REVIEW; HUMAN;

EID: 85075002014     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/s41392-019-0074-5     Document Type: Review

References (539)

1. Sarin, S. K., Pande, A. & Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol. 70, 260–272 (2019).
2. Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164, 337–340 (2016).
3. Biragyn, A. & Ferrucci, L. Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging. Lancet Oncol. 19, e295–e304 (2018).
4. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
5. International Human Genome Sequencing Consortium. Finishing the euchro-matic sequence of the human genome. Nature 431, 931–945 (2004).
6. Nayfach, S., Shi, Z. J., Seshadri, R., Pollard, K. S. & Kyrpides, N. C. New insights from uncultivated genomes of the global human gut microbiome. Nature 568, 505–510 (2019).
7. Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499–504 (2019).
8. Zeevi, D. et al. Structural variation in the gut microbiome associates with host health. Nature 568, 43–48 (2019).
9. Dou, J. et al. Microbiosis in pathogenesis and intervention of atopic dermatitis. Int. Immunopharmacol. 69, 263–269 (2019).
10. Seth, P. et al. Regulation of microRNA machinery and development by interspecies S-nitrosylation. Cell 176, 1014–1025.e1012 (2019).
11. Kim, M. et al. Critical role for the microbiota in CX3CR1(+) intestinal mononuclear phagocyte regulation of intestinal T cell responses. Immunity 49, 151–163.e155 (2018).
12. Zhu, C. et al. Roseburia intestinalis inhibits interleukin17 excretion and promotes regulatory T cells differentiation in colitis. Mol. Med. Rep. 17, 7567–7574 (2018).
13. Dodd, D. et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551, 648–652 (2017).
14. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Backhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332–1345 (2016).
15. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).
16. Sharon, G. et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell 177, 1600–1618.e1617 (2019).
17. Peng, W. et al. Association of gut microbiota composition and function with a senescence-accelerated mouse model of Alzheimer's disease using 16S rRNA gene and metagenomic sequencing analysis. Aging (Albany, NY) 10, 4054–4065 (2018).
18. Zhang, X. et al. Fructose malabsorption induces cholecystokinin expression in the ileum and cecum by changing microbiota composition and metabolism. FASEB J. https://doi.org/10.1096/fj.201801526RR (2019).
19. Tyagi, A. M. et al. The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression. Immunity 49, 1116–1131.e1117 (2018).
20. Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science (New York, NY) 364, https://doi.org/10.1126/science. aau6323 (2019).
21. Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462–467 (2019).
22. Britton, G. J. et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORgammat(+) regulatory T cells and exacerbate colitis in mice. Immunity 50, 212–224.e214 (2019).
23. Garrett, W. S. The gut microbiota and colon cancer. Science (New York, NY) 364, 1133–1135 (2019).
24. Valles-Colomer, M. et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol. 4, 623–632 (2019).
25. Paun, A. et al. Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children. Sci. Immunol. 4, https://doi.org/10.1126/sciimmunol.aau8125 (2019).
26. Azzouz, D. et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann. Rheum. Dis. 78, 947–956 (2019).
27. Abdel-Gadir, A. et al. Microbiota therapy acts via a regulatory T cell MyD88/ RORgammat pathway to suppress food allergy. Nat. Med. 25, 1164–1174 (2019).
28. Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103 (2019).
29. De Filippis, F. et al. Distinct genetic and functional traits of human intestinal prevotella copri strains are associated with different habitual diets. Cell Host Microbe 25, 444–453.e443 (2019).
30. Abbasi, J. TMAO and heart disease: the new red meat risk? JAMA https://doi.org/10.1001/jama.2019.3910 (2019).
31. Delzenne, N. M. & Bindels, L. B. Microbiome metabolomics reveals new drivers of human liver steatosis. Nat. Med. 24, 906–907 (2018).
32. Singh, V. et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver. Cancer Cell 175, 679–694.e622 (2018).
33. Luu, T. H. et al. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell Oncol. (Dordr.) 41, 13–24 (2018).
34. Riquelme, E., Maitra, A. & McAllister, F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 8, 386–388 (2018).
35. Li, Y. et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5(−/−) mice. Nat. Commun. 10, 1492 (2019).
36. Ludwig, I. S. et al. Lactobacillus rhamnosus GG-derived soluble mediators modulate adaptive immune cells. Front. Immunol. 9, 1546 (2018).
37. Ansaldo, E. et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science (New York, NY) 364, 1179–1184 (2019).
38. Yan, B. et al. Activation of AhR with nuclear IKKalpha regulates cancer stem-like properties in the occurrence of radioresistance. Cell Death Dis. 9, 490 (2018).
39. Roy, U. et al. Distinct microbial communities trigger colitis development upon intestinal barrier damage via innate or adaptive immune cells. Cell Rep. 21, 994–1008 (2017).
40. Kim, K. S. et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science (New York, NY) 351, 858–863 (2016).
41. Mao, K. et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature 554, 255–259 (2018).
42. Galvez, E. J. C., Iljazovic, A., Gronow, A., Flavell, R. & Strowig, T. Shaping of intestinal microbiota in Nlrp6-and Rag2-deficient mice depends on community structure. Cell Rep. 21, 3914–3926 (2017).
43. Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anticancer immunity. Nature 565, 600–605 (2019).
44. Martin, R. et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front. Microbiol. 8, 1226 (2017).
45. Eeckhaut, V. et al. Anaerostipes butyraticus sp. nov., an anaerobic, butyrate-producing bacterium from Clostridium cluster XIVa isolated from broiler chicken caecal content, and emended description of the genus Anaerostipes. Int. J. Syst. Evolut. Microbiol. 60, 1108–1112 (2010).
46. Xiao, M. et al. A new colitis therapy strategy via the target colonization of magnetic nanoparticle-internalized Roseburia intestinalis. Biomater. Sci. https://doi.org/10.1039/c9bm00980a (2019).
47. Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science (New York, NY) 359, 1151–1156 (2018).
48. Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P. & Macfarlane, G. T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227 (1987).
49. Al Nabhani, Z. et al. A weaning reaction to microbiota is required for resistance to immunopathologies in the adult. Immunity 50, 1276–1288.e1275 (2019).
50. Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
51. Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (New York, NY) 341, 569–573 (2013).
52. Macia, L. et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).
53. Nowarski, R. et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell 163, 1444–1456 (2015).
54. Fujiwara, H. et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat. Commun. 9, 3674 (2018).
55. Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128–139 (2014).
56. Verma, M. S. et al. A common mechanism links activities of butyrate in the colon. ACS Chem. Biol. 13, 1291–1298 (2018).
57. Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).
58. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).
59. Martin-Gallausiaux, C. et al. Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells. Sci. Rep. 8, 9742 (2018).
60. Mowat, A. M. To respond or not to respond—a personal perspective of intestinal tolerance. Nat. Rev. Immunol. 18, 405–415 (2018).
61. Skelly, A. N., Sato, Y., Kearney, S. & Honda, K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol. 19, 305–323 (2019).
62. Konieczna, P. et al. Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms. PLoS ONE 8, e62617 (2013).
63. Park, J. et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 8, 80–93 (2015).
64. Sun, M. et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat. Commun. 9, 3555 (2018).
65. Chen, L. et al. Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells’ differentiation and function in induction of colitis. Inflamm. Bowel Dis. 25, 1450–1461 (2019).
66. Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells. Immunity https://doi.org/10.1016/j.immuni.2019.06.002 (2019).
67. Kim, M., Qie, Y., Park, J. & Kim, C. H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe 20, 202–214 (2016).
68. Kim, C. H. B cell-helping functions of gut microbial metabolites. Microbial Cell 3, 529–531 (2016).
69. Yang, W. et al. Microbiota metabolite short-chain fatty acids facilitate mucosal adjuvant activity of cholera toxin through GPR43. J. Immunol. https://doi.org/10.4049/jimmunol.1801068 (2019).
70. McLoughlin, K., Schluter, J., Rakoff-Nahoum, S., Smith, A. L. & Foster, K. R. Host selection of microbiota via differential adhesion. Cell Host Microbe 19, 550–559 (2016).
71. Donaldson, G. P. et al. Gut microbiota utilize immunoglobulin A for mucosal colonization. Science (New York, NY) 360, 795–800 (2018).
72. Wu, W. et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol. 10, 946–956 (2017).
73. Schulthess, J. et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50, 432–445.e437 (2019).
74. Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 111, 2247–2252 (2014).
75. Scott, N. A. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl. Med. 10, eaao4775 (2018).
76. Ji, J. et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci. Rep. 6, 24838 (2016).
77. Chen, F. & Stappenbeck, T. S. Microbiome control of innate reactivity. Curr. Opin. Immunol. 56, 107–113 (2019).
78. Byndloss, M. X. et al. Microbiota-activated PPAR-gamma signaling inhibits dys-biotic Enterobacteriaceae expansion. Science (New York, NY) 357, 570–575 (2017).
79. Litvak, Y., Byndloss, M. X. & Baumler, A. J. Colonocyte metabolism shapes the gut microbiota. Science (New York, NY) 362, eaat9076 (2018).
80. Winter, S. E. et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science (New York, NY) 339, 708–711 (2013).
81. Jacobson, A. et al. A gut commensal-produced metabolite mediates colonization resistance to Salmonella infection. Cell Host Microbe 24, 296–307.e297 (2018).
82. Sorbara, M. T. et al. Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification. J. Exp. Med. 216, 84–98 (2019).
83. Gillis, C. C. et al. Dysbiosis-associated change in host metabolism generates lactate to support Salmonella growth. Cell host microbe 23, 54–64.e56 (2018).
84. Tan, B. et al. Roseburia intestinalis inhibits oncostatin M and maintains tight junction integrity in a murine model of acute experimental colitis. Scand. J. Gastroenterol. 54, 432–440 (2019).
85. Birchenough, G. M., Nystrom, E. E., Johansson, M. E. & Hansson, G. C. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science (New York, NY) 352, 1535–1542 (2016).
86. Ranson, N. et al. Nod-like receptor pyrin-containing protein 6 (NLRP6) is up-regulated in ileal Crohn’s disease and differentially expressed in goblet cells. Cell Mol. Gastroenterol. Hepatol. 6, 110–112.e118 (2018).
87. Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic host–microbial interface by regulating goblet cell mucus secretion. Cell 156, 1045–1059 (2014).
88. Mathewson, N. D. et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat. Immunol. 17, 505–513 (2016).
89. Gonzalez, A. et al. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression. Nephrol. Dial. Transpl. 34, 783–794 (2019).
90. Zheng, L. et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J. Immunol. 199, 2976–2984 (2017).
91. Zhao, Y. et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 11, 752–762 (2018).
92. Cobo, E. R., Kissoon-Singh, V., Moreau, F., Holani, R. & Chadee, K. MUC2 mucin and butyrate contribute to the synthesis of the antimicrobial peptide cathe-licidin in response to Entamoeba histolytica-and dextran sodium sulfate-induced colitis. Infect. Immun. 85, e00905-16 (2017).
93. Fachi, J. L. et al. Butyrate protects mice from Clostridium difficile-induced colitis through an HIF-1-dependent mechanism. Cell Rep. 27, 750–761.e757 (2019).
94. Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339–1353.e1321 (2016).
95. Schroeder, B. O. et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23, 27–40. e27 (2018).
96. Zou, J. et al. Fiber-mediated nourishment of gut microbiota protects against diet-induced obesity by restoring IL-22-mediated colonic health. Cell Host Microbe 23, 41–53.e44 (2018).
97. Wan, Y. et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. Gut https://doi.org/10.1136/gutjnl-2018-317609 (2019).
98. Kaiko, G. E. et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell 165, 1708–1720 (2016).
99. Singh, V. et al. Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation. Gut https://doi.org/10.1136/gutjnl-2018-316250 (2019).
100. Truax, A. D. et al. The inhibitory innate immune sensor NLRP12 maintains a threshold against obesity by regulating gut microbiota homeostasis. Cell Host Microbe 24, 364–378.e366 (2018).
101. Bodogai, M. et al. Commensal bacteria contribute to insulin resistance in aging by activating innate B1acells. Sci. Transl. Med. 10, https://doi.org/10.1126/scitranslmed.aat4271 (2018).
102. Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51, 600–605 (2019).
103. Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744–1754 (2015).
104. Canfora, E. E. et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci. Rep. 7, 2360 (2017).
105. Brooks, L. et al. Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansion to increase satiety. Mol. Metab. 6, 48–60 (2017).
106. Fluitman, K. S., Wijdeveld, M., Nieuwdorp, M. & RG, I. J. Potential of butyrate to influence food intake in mice and men. Gut 67, 1203–1204 (2018).
107. Li, Z. et al. Butyrate reduces appetite and activates brown adipose tissue via the gut–brain neural circuit. Gut 67, 1269–1279 (2018).
108. Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).
109. Canfora, E. E., Meex, R. C. R., Venema, K. & Blaak, E. E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261–273 (2019).
110. Perry, R. J. et al. Acetate mediates a microbiome–brain-beta-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016).
111. Singh, V. et al. Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice. Cell Metab. 22, 983–996 (2015).
112. De Vadder, F. et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156, 84–96 (2014).
113. Whitt, J. et al. Disruption of epithelial HDAC3 in intestine prevents diet-induced obesity in mice. Gastroenterology 155, 501–513 (2018).
114. Kasahara, K. et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat. Microbiol 3, 1461–1471 (2018).
115. Kamareddine, L., Robins, W. P., Berkey, C. D., Mekalanos, J. J. & Watnick, P. I. The Drosophila immune deficiency pathway modulates enteroendocrine function and host metabolism. Cell Metab. 28, 449–462.e445 (2018).
116. Li, B. et al. Microbiota depletion impairs thermogenesis of brown adipose tissue and browning of white adipose tissue. Cell Rep. 26, 2720–2737.e2725 (2019).
117. Scheiman, J. et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. Nat. Med. https://doi. org/10.1038/s41591-019-0485-4 (2019).
118. Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965–977 (2015).
119. Chen, T., Noto, D., Hoshino, Y., Mizuno, M. & Miyake, S. Butyrate suppresses demyelination and enhances remyelination. J. Neuroinflamm. 16, 165 (2019).
120. Chen, R. et al. Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota. Pharmacol. Res. https://doi.org/10.1016/j.phrs.2019.104403 (2019).
121. Braniste, V. et al. The gut microbiota influences blood–brain barrier permeability in mice. Sci. Transl. Med. 6, 263ra158 (2014).
122. Hoyles, L. et al. Microbiome–host systems interactions: protective effects of propionate upon the blood-brain barrier. Microbiome 6, 55 (2018).
123. Li, J. M. et al. Dietary fructose-induced gut dysbiosis promotes mouse hippo-campal neuroinflammation: a benefit of short-chain fatty acids. Microbiome 7,98 (2019).
124. Zhang, Q. et al. Intestinal lysozyme liberates Nod1 ligands from microbes to direct insulin trafficking in pancreatic beta cells. Cell Res. 29, 516–532 (2019).
125. Sorini, C. et al. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. Proc. Natl. Acad. Sci. USA https://doi.org/10.1073/pnas.1814558116 (2019).
126. Vatanen, T. et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562, 589–594 (2018).
127. Marino, E. et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017).
128. Miani, M. et al. Gut microbiota-stimulated innate lymphoid cells support beta-defensin 14 expression in pancreatic endocrine cells, preventing autoimmune diabetes. Cell Metab. 28, 557–572.e556 (2018).
129. Zegarra-Ruiz, D. F. et al. A diet-sensitive commensal Lactobacillus strain mediates TLR7-dependent systemic autoimmunity. Cell Host Microbe 25, 113–127. e116 (2019).
130. Haak, B. W. et al. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131, 2978–2986 (2018).
131. Antunes, K. H. et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. Nat. Commun. 10, 3273 (2019).
132. Trompette, A. et al. Dietary fiber confers protection against flu by shaping Ly6c (−) patrolling monocyte hematopoiesis and CD8(+) T cell metabolism. Immunity 48, 992–1005.e1008 (2018).
133. Lucas, S. et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. Nat. Commun. 9, 55 (2018).
134. Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 9, 3294 (2018).
135. Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598–605 (2016).
136. Nikolaus, S. et al. Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. Gastroenterology 153, 1504–1516.e1502 (2017).
137. Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385 (2013).
138. Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264–276 (2015).
139. Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716–724 (2018).
140. Lv, Q. et al. Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation. Cell Death Dis. 9, 890 (2018).
141. Metidji, A. et al. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 49, 353–362.e355 (2018).
142. Schiering, C. et al. Feedback control of AHR signalling regulates intestinal immunity. Nature 542, 242–245 (2017).
143. Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial CD4 (+)CD8alphaalpha(+) T cells. Science (New York, NY) 357, 806–810 (2017).
144. Swimm, A. et al. Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood 132, 2506–2519 (2018).
145. Teng, Y. et al. Plant-derived exosomal microRNAs shape the gut microbiota. Cell Host Microbe 24, 637–652.e638 (2018).
146. Kumar, A. & Sperandio, V. Indole signaling at the host–microbiota–pathogen interface. mBio 10, https://doi.org/10.1128/mBio.01031-19 (2019).
147. Kohli, N. et al. The microbiota metabolite indole inhibits Salmonella virulence: involvement of the PhoPQ two-component system. PLoS ONE 13, e0190613 (2018).
148. Wlodarska, M. et al. Indoleacrylic acid produced by commensal Peptos-treptococcus species suppresses inflammation. Cell Host Microbe 22, 25–37.e26 (2017).
149. Birchenough, G. & Hansson, G. C. Bacteria tell us how to protect our intestine. Cell Host Microbe 22, 3–4 (2017).
150. Jennis, M. et al. Microbiota-derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo. Neuro-gastroenterol. Motil. 30, https://doi.org/10.1111/nmo.13178 (2018).
151. Venkatesh, M. et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41, 296–310 (2014).
152. Negatu, D. A. et al. Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in Mycobacterium tuberculosis. mBio 10, https://doi.org/10.1128/mBio.02781-18 (2019).
153. Iyer, S. S. et al. Dietary and microbial oxazoles induce intestinal inflammation by modulating aryl hydrocarbon receptor responses. Cell 173, 1123–1134.e1111 (2018).
154. Laurans, L. et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat. Med. 24, 1113–1120 (2018).
155. Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 19, 184–197 (2019).
156. Nourbakhsh, B. et al. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann. Clin. Transl. Neurol. 5, 1211–1221 (2018).
157. Rothhammer, V. et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724–728 (2018).
158. Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597 (2016).
159. Wekerle, H. Brain inflammatory cascade controlled by gut-derived molecules. Nature 557, 642–643 (2018).
160. Marsland, B. J. Regulating inflammation with microbial metabolites. Nat. Med. 22, 581–583 (2016).
161. Beaumont, M. et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. Faseb J. https://doi.org/10.1096/fj.201800544 (2018).
162. Krishnan, S. et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep. 23, 1099–1111 (2018).
163. Hendrikx, T. et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut 68, 1504–1515 (2018).
164. Natividad, J. M. et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 28, 737–749.e734 (2018).
165. Virtue, A. T. et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Sci. Transl. Med. 11, https://doi. org/10.1126/scitranslmed.aav1892 (2019).
166. Chimerel, C. et al. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 9, 1202–1208 (2014).
167. Williams, B. B. et al. Discovery and characterization of gut microbiota dec-arboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16, 495–503 (2014).
168. Bhattarai, Y. et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe 23, 775–785.e775 (2018).
169. Cryan, J. F., Clarke, G., Dinan, T. G. & Schellekens, H. A microbial drugstore for motility. Cell Host Microbe 23, 691–692 (2018).
170. Cohen, L. J. et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549, 48–53 (2017).
171. Chen, H. et al. A forward chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell 177, 1217–1231.e1218 (2019).
172. Jia, W., Xie, G. & Jia, W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111–128 (2018).
173. Jain, U. et al. Temporal regulation of the bacterial metabolite deoxycholate during colonic repair is critical for crypt regeneration. Cell Host Microbe 24, 353–363.e355 (2018).
174. Wang, K. et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 26, 222–235.e225 (2019).
175. Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).
176. Greathouse, K. L., Harris, C. C. & Bultman, S. J. Dysfunctional families: Clostridium scindens and secondary bile acids inhibit the growth of Clostridium difficile. Cell Metab. 21, 9–10 (2015).
177. Sun, X. et al. Microbiota-derived metabolic factors reduce Campylobacteriosis in mice. Gastroenterology 154, 1751–1763.e1752 (2018).
178. Kang, J. D. et al. Bile Acid 7alpha-dehydroxylating gut bacteria secrete antibiotics that inhibit clostridium difficile: role of secondary bile acids. Cell Chem. Biol. 26, 27–34.e24 (2019).
179. McKenney, P. T. et al. Intestinal bile acids induce a morphotype switch in vancomycin-resistant Enterococcus that facilitates intestinal colonization. Cell Host Microbe 25, 695–705.e695 (2019).
180. Weingarden, A. R. et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pou-chitis associated with the infection. J. Clin. Gastroenterol. 50, 624–630 (2016).
181. Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679–689 (2019).
182. Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968–976 (2019).
183. Fu, T. et al. FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098–1112.e1018 (2019).
184. Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97–101 (2013).
185. Bourzac, K. Microbiome: the bacterial tightrope. Nature 516, S14–S16 (2014).
186. Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science (New York, NY) 360, https://doi.org/10.1126/science. aan5931 (2018).
187. Hartmann, N. & Kronenberg, M. Cancer immunity thwarted by the microbiome. Science (New York, NY) 360, 858–859 (2018).
188. Mossanen, J. C. et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T-and CD4(+) T-cell-dependent control of senescence. Gastroenterology 156, 1877–1889.e1874 (2019).
189. Liao, X. et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EbioMedicine https://doi.org/10.1016/j.ebiom.2019.03.057 (2019).
190. De Vadder, F. et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab. 24, 151–157 (2016).
191. Mills, E. L. et al. Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560, 102–106 (2018).
192. Hui, S. & Rabinowitz, J. D. An unexpected trigger for calorie burning in brown fat. Nature 560, 38–39 (2018).
193. Serena, C. et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 12, 1642–1657 (2018).
194. Zhang, J. et al. Intestinal microbiota are involved in the immunomodulatory activities of longan polysaccharide. Mol. Nutr. Food Res. 61, 1700466 (2017).
195. Haraguchi, T. et al. Cecal succinate elevated by some dietary polyphenols may inhibit colon cancer cell proliferation and angiogenesis. J. Agric. Food Chem. 62, 5589–5594 (2014).
196. Schneider, C. et al. A metabolite-triggered tuft cell-ILC2 circuit drives small intestinal remodeling. Cell 174, 271–284.e214 (2018).
197. Nadjsombati, M. S. et al. Detection of succinate by intestinal tuft cells triggers a type 2 innate immune circuit. Immunity 49, 33–41.e37 (2018).
198. Lei, W. et al. Activation of intestinal tuft cell-expressed Sucnr1 triggers type 2 immunity in the mouse small intestine. Proc. Natl. Acad. Sci. USA 115, 5552–5557 (2018).
199. Hayakawa, Y. & Wang, T. C. The tuft cell-ILC2 circuit integrates intestinal defense and homeostasis. Cell 174, 251–253 (2018).
200. Loke, P. & Cadwell, K. Getting a taste for parasites in the gut. Immunity 49,16–18 (2018).
201. Macias-Ceja, D. C. et al. Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunol. 12, 178–187 (2019).
202. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496, 238–242 (2013).
203. Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457–470.e413 (2016).
204. Morita, N. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1(+) cells by bacterial metabolites. Nature 566, 110–114 (2019).
205. Mao, N., Cubillos-Ruiz, A., Cameron, D. E. & Collins, J. J. Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 10, eaao258 (2018).
206. Lee, Y. S. et al. Microbiota-derived lactate accelerates intestinal stem-cell-mediated epithelial development. Cell Host Microbe 24, 833–846.e836 (2018).
207. Iatsenko, I., Boquete, J. P. & Lemaitre, B. Microbiota-derived lactate activates production of reactive oxygen species by the intestinal NADPH oxidase Nox and shortens drosophila lifespan. Immunity 49, 929–942.e925 (2018).
208. Milshteyn, A., Colosimo, D. A. & Brady, S. F. Accessing bioactive natural products from the human microbiome. Cell Host Microbe 23, 725–736 (2018).
209. Steed, A. L. et al. The microbial metabolite ne protects from influenza through type I interferon. Science (New York, NY) 357, 498–502 (2017).
210. Kuss, S. K. et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science (New York, NY) 334, 249–252 (2011).
211. Lobel, L. & Garrett, W. S. Take DAT, flu! Immunity 47, 400–402 (2017).
212. Chang, Y. L. et al. A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol. 12, 457–467 (2019).
213. Reticker-Flynn, N. E. & Engleman, E. G. A gut punch fights cancer and infection. Nature 565, 573–574 (2019).
214. Singh, R. et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat. Commun. 10, 89 (2019).
215. Andreux, P. A. et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat. Metab. 1, 595–603 (2019).
216. Levy, M. et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163, 1428–1443 (2015).
217. Connolly, J. P. R. et al. Host-associated niche metabolism controls enteric infection through fine-tuning the regulation of type 3 secretion. Nat. Commun. 9, 4187 (2018).
218. Koh, A. et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175, 947–961.e917 (2018).
219. Kikuchi, K. et al. Gut microbiome-derived phenyl sulfate contributes to albu-minuria in diabetic kidney disease. Nat. Commun. 10, 1835 (2019).
220. Nicolas, G. R. & Chang, P. V. Deciphering the chemical lexicon of host–gut microbiota interactions. Trends Pharm. Sci. 40, 430–445 (2019).
221. Esterhazy, D. et al. Compartmentalized gut lymph node drainage dictates adaptive immune responses. Nature 569, 126–130 (2019).
222. Rubtsov, Y. P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546–558 (2008).
223. Huber, S. et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(–) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34, 554–565 (2011).
224. Park, S. G. et al. T regulatory cells maintain intestinal homeostasis by suppressing gammadelta T cells. Immunity 33, 791–803 (2010).
225. Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science (New York, NY) 331, 337–341 (2011).
226. Round, J. L. & Mazmanian, S. K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. USA 107, 12204–12209 (2010).
227. Geuking, M. B. et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34, 794–806 (2011).
228. Ohnmacht, C. et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science (New York, NY) 349, 989–993 (2015).
229. Yang, B. H. et al. Foxp3(+) T cells expressing RORgammat represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol. 9, 444–457 (2016).
230. Torres, J. et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut https://doi.org/10.1136/gutjnl-2018-317855 (2019).
231. Campbell, C. et al. Extrathymically generated regulatory T cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity 48, 1245–1257.e1249 (2018).
232. Xu, M. et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554, 373–377 (2018).
233. Neumann, C. et al. c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host-microbiota homeostasis. Nat. Immunol. 20, 471–481 (2019).
234. Chai, J. N. et al. Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation. Sci. Immunol. 2, eaal5068 (2017).
235. Sefik, E. et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science (New York, NY) 349, 993–997 (2015).
236. Gefen, T. & Geva-Zatorsky, N. What came first: the microbiota or the Tr(egg) cells? Immunity 48, 1072–1074 (2018).
237. Obata, Y. et al. The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. Nat. Immunol. 15, 571–579 (2014).
238. Bennek, E. et al. Subcellular antigen localization in commensal E. coli is critical for T cell activation and induction of specific tolerance. Mucosal Immunol. 12, 97–107 (2019).
239. Telesford, K. M. et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes 6, 234–242 (2015).
240. Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008).
241. Round, J. L. et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science (New York, NY) 332, 974–977 (2011).
242. Chu, H. et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science (New York, NY) 352, 1116–1120 (2016).
243. Bel, S. et al. Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine. Science (New York, NY) 357, 1047–1052 (2017).
244. Kabat, A. M. et al. The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation. Elife 5, e12444 (2016).
245. Pott, J., Kabat, A. M. & Maloy, K. J. Intestinal epithelial cell autophagy is required to protect against TNF-induced apoptosis during chronic colitis in mice. Cell Host Microbe 23, 191–202.e194 (2018).
246. Grizotte-Lake, M. & Vaishnava, S. Autophagy: suicide prevention hotline for the gut epithelium. Cell Host Microbe 23, 147–148 (2018).
247. McCoy, K. D., Ronchi, F. & Geuking, M. B. Host-microbiota interactions and adaptive immunity. Immunol. Rev. 279, 63–69 (2017).
248. Stefka, A. T. et al. Commensal bacteria protect against food allergen sensitization. Proc. Natl. Acad. Sci. USA 111, 13145–13150 (2014).
249. Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
250. Quan, Y. et al. Roseburia intestinalis-derived flagellin is a negative regulator of intestinal inflammation. Biochem. Biophys. Res. Commun. 501, 791–799 (2018).
251. Ruff, W. E. et al. Pathogenic autoreactive T and B cells cross-react with mimo-topes expressed by a common human gut commensal to trigger autoimmunity. Cell Host Microbe 26, 100–113.e8 (2019).
252. An, D. et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156, 123–133 (2014).
253. Chan, J. L. et al. Non-toxigenic Bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide A. Mucosal Immunol. 12, 164–177 (2019).
254. Mu, Q., Tavella, V. J. & Luo, X. M. Role of Lactobacillus reuteri in human health and diseases. Front. Microbiol. 9, 757 (2018).
255. Verma, R. et al. Cell surface polysaccharides of Bifidobacterium bifidum induce the generation of Foxp3(+) regulatory T cells. Sci. Immunol. 3, https://doi.org/10.1126/sciimmunol.aat6975 (2018).
256. Zhai, R. et al. Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice. Front. Cell Infect. Microbiol. 9, 239 (2019).
257. Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75–84 (2016).
258. Harrison, O. J. et al. Commensal-specific T cell plasticity promotes rapid tissue adaptation to injury. Science (New York, NY) 363, https://doi.org/10.1126/science. aat6280 (2019).
259. Omenetti, S. et al. The intestine harbors functionally distinct homeostatic tissue-resident and inflammatory Th17 cells. Immunity https://doi.org/10.1016/j. immuni.2019.05.004 (2019).
260. Saleh, M. M. et al. Colitis-induced Th17 cells increase the risk for severe subsequent Clostridium difficile infection. Cell Host Microbe 25, 756–765.e755 (2019).
261. Kim, S. et al. Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. Nature 549, 528–532 (2017).
262. Calcinotto, A. et al. Microbiota-driven interleukin-17-producing cells and eosi-nophils synergize to accelerate multiple myeloma progression. Nat. Commun. 9, 4832 (2018).
263. Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell 176, 1340–1355.e1315 (2019).
264. Shao, T. Y. et al. Commensal Candida albicans positively calibrates systemic Th17 immunological responses. Cell Host Microbe 25, 404–417.e406 (2019).
265. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
266. Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008).
267. Atarashi, K. et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 455, 808–812 (2008).
268. Sano, T. et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell 163, 381–393 (2015).
269. Atarashi, K. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015).
270. Ladinsky, M. S. et al. Endocytosis of commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis. Science (New York, NY) 363 https://doi.org/10.1126/science.aat4042 (2019).
271. Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538–541 (2011).
272. Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalo-myelitis. Proc. Natl. Acad. Sci. USA 108(Suppl. 1), 4615–4622 (2011).
273. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815–827 (2010).
274. Lecuyer, E. et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. Immunity 40, 608–620 (2014).
275. Kumar, P. et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity 44, 659–671 (2016).
276. Yang, Y. et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510, 152–156 (2014).
277. Tan, T. G. et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc. Natl. Acad. Sci. USA 113, E8141–E8150 (2016).
278. Colliou, N. et al. Commensal propionibacterium strain UF1 mitigates intestinal inflammation via Th17 cell regulation. J. Clin. Investig. 127, 3970–3986 (2017).
279. Wilck, N. et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature 551, 585–589 (2017).
280. Bartolomaeus, H. et al. Short-chain fatty acid propionate protects from hyper-tensive cardiovascular damage. Circulation 139, 1407–1421 (2019).
281. Faraco, G. et al. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response. Nat. Neurosci. 21, 240–249 (2018).
282. Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science (New York, NY) 358, 359–365 (2017).
283. Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 487, 104–108 (2012).
284. Rutz, S. et al. Notch regulates IL-10 production by T helper 1 cells. Proc. Natl. Acad. Sci. USA 105, 3497–3502 (2008).
285. Pickard, J. M., Zeng, M. Y., Caruso, R. & Nunez, G. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol. Rev. 279, 70–89 (2017).
286. Jie, Z. et al. NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis. Nat. Immunol. 19, 1224–1235 (2018).
287. Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease.
288. Ma, N. et al. Nutrients mediate intestinal bacteria-mucosal immune crosstalk. Front. Immunol. 9, 5 (2018).
289. Matsuo, K. et al. CCL28-deficient mice have reduced iga antibody-secreting cells and an altered microbiota in the colon. J. Immunol. 200, 800–809 (2018).
290. Grootjans, J. et al. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. Science (New York, NY) 363, 993–998 (2019).
291. Hapfelmeier, S. et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science (New York, NY) 328, 1705–1709 (2010).
292. Hedblom, G. A., Reiland, H. A., Sylte, M. J., Johnson, T. J. & Baumler, D. J. Segmented filamentous bacteria—metabolism meets immunity. Front. Microbiol. 9, 1991 (2018).
293. Cho, H. et al. Defective IgA response to atypical intestinal commensals in IL-21 receptor deficiency reshapes immune cell homeostasis and mucosal immunity. Mucosal Immunol. 12, 85–96 (2019).
294. Kawashima, T. et al. The molecular mechanism for activating IgA production by Pediococcus acidilactici K15 and the clinical impact in a randomized trial. Sci. Rep. 8, 5065 (2018).
295. Wilmore, J. R. et al. Commensal microbes induce serum IgA responses that protect against polymicrobial sepsis. Cell Host Microbe 23, 302–311.e303 (2018).
296. Rojas, O. L. et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell 176, 610–624.e618 (2019).
297. Li, B., Selmi, C., Tang, R., Gershwin, M. E. & Ma, X. The microbiome and autoimmunity: a paradigm from the gut–liver axis. Cell Mol. Immunol. 15, 595–609 (2018).
298. Moor, K. et al. High-avidity IgA protects the intestine by enchaining growing bacteria. Nature 544, 498–502 (2017).
299. Hansen, I. S. et al. FcalphaRI co-stimulation converts human intestinal CD103(+) dendritic cells into pro-inflammatory cells through glycolytic reprogramming. Nat. Commun. 9, 863 (2018).
300. Proietti, M. et al. ATP released by intestinal bacteria limits the generation of protective IgA against enteropathogens. Nat. Commun. 10, 250 (2019).
301. Chagwedera, D. N. et al. Nutrient sensing in CD11c cells alters the gut microbiota to regulate food intake and body mass. Cell Metab. https://doi.org/10.1016/j.cmet.2019.05.002 (2019).
302. Nakajima, A. et al. IgA regulates the composition and metabolic function of gut microbiota by promoting symbiosis between bacteria. J. Exp. Med. 215, 2019–2034 (2018).
303. Fadlallah, J. et al. Microbial ecology perturbation in human IgA deficiency. Sci. Transl. Med. 10, eaan1167 (2018).
304. Schofield, W. B. & Palm, N. W. Gut microbiota: IgA protects the pioneers. Curr. Biol. 28, R1117–R1119 (2018).
305. IgAte our intestinal microbes. Sci. Immunol. 3, eaat4037 (2018).
306. Pokrovskii, M. et al. Characterization of transcriptional regulatory networks that promote and restrict identities and functions of intestinal innate lymphoid cells. Immunity https://doi.org/10.1016/j.immuni.2019.06.001 (2019).
307. Gury-BenAri, M. et al. The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. Cell 166, 1231–1246. e1213 (2016).
308. Emgard, J. et al. Oxysterol sensing through the receptor GPR183 promotes the lymphoid-tissue-inducing function of innate lymphoid cells and colonic inflammation. Immunity 48, 120–132.e128 (2018).
309. Hepworth, M. R. et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498, 113–117 (2013).
310. Kruglov, A. A. et al. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science (New York, NY) 342, 1243–1246 (2013).
311. Deng, T. et al. ILC3-derived OX40L is essential for homeostasis of intestinal Tregs in immunodeficient mice. Cell Mol. Immunol. https://doi.org/10.1038/s41423-019-0200-x (2019).
312. Hepworth, M. R. et al. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells. Science (New York, NY) 348, 1031–1035 (2015).
313. Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science (New York, NY) 343, 1249288 (2014).
314. Aychek, T. & Jung, S. Immunology axis tolerance. Science (New York, NY) 343, 1439–1440 (2014).
315. Zhou, L. et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature 568, 405–409 (2019).
316. Martinez-Lopez, M. et al. Microbiota sensing by Mincle-Syk axis in dendritic cells regulates interleukin-17 and-22 production and promotes intestinal barrier integrity. Immunity 50, 446–461.e449 (2019).
317. Ibiza, S. et al. Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. Nature 535, 440–443 (2016).
318. Bogunovic, M. ILC3s and the Willow tree of voices. Immunity 45, 238–239 (2016).
319. Goto, Y. et al. Innate lymphoid cells regulate intestinal epithelial cell glycosy-lation. Science (New York, NY) 345, 1254009 (2014).
320. Tsai, P. Y. et al. IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance. Cell Host Microbe 21, 671–681.e674 (2017).
321. Fatkhullina, A. R. et al. An interleukin-23–interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity 49, 943–957.e949 (2018).
322. Seo, G. Y. et al. LIGHT-HVEM signaling in innate lymphoid cell subsets protects against enteric bacterial infection. Cell Host Microbe 24, 249–260.e244 (2018).
323. Hernandez, P. P. et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 16, 698–707 (2015).
324. Lindemans, C. A. et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 528, 560–564 (2015).
325. Hou, Q. et al. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22. Cell Death Differ. 25, 1657–1670 (2018).
326. Gronke, K. et al. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature 566, 249–253 (2019).
327. Duffin, R. et al. Prostaglandin E(2) constrains systemic inflammation through an innate lymphoid cell–IL-22 axis. Science (New York, NY) 351, 1333–1338 (2016).
328. Wang, B. et al. Macrophage beta2-integrins regulate IL-22 by ILC3s and protect from lethal Citrobacter rodentium-induced colitis. Cell Rep. 26, 1614–1626.e1615 (2019).
329. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010).
330. Bernshtein, B. et al. IL-23-producing IL-10Ralpha-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response. Sci. Immunol. 4, https://doi.org/10.1126/sciimmunol.aau6571 (2019).
331. Grizotte-Lake, M. et al. Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate interleukin-22 activity and prevent microbial dysbiosis. Immunity 49, 1103–1115.e1106 (2018).
332. Mathur, R. et al. Induction of autophagy in Cx3cr1(+) mononuclear cells limits IL-23/IL-22 axis-mediated intestinal fibrosis. Mucosal Immunol. 12, 612–623 (2019).
333. Castellanos, J. G. et al. Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity 49, 1077–1089.e1075 (2018).
334. Lv, Y. P. et al. Helicobacter pylori-induced matrix metallopeptidase-10 promotes gastric bacterial colonization and gastritis. Sci. Adv. 5, eaau6547 (2019).
335. Bauche, D. et al. LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity 49, 342–352.e345 (2018).
336. Pantazi, E. & Powell, N. Group 3 ILCs: peacekeepers or troublemakers? What's your gut telling you?! Front. Immunol. 10, 676 (2019).
337. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
338. Yang, R. et al. LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 38, 280 (2019).
339. Mao, C. et al. Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6 expression in NSCLC. Am. J. Cancer Res. 8, 1214–1227 (2018).
340. Jiang, Y. et al. Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. Oncogene 34, 6079–6091 (2015).
341. He, X. et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res. 76, 5743–5755 (2016).
342. Yang, R. et al. GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH. Oncogene https://doi.org/10.1038/s41388-019-0909-0 (2019).
343. Ouyang, C. et al. Chromatin remodeling factor lymphoid-specific helicase links with Epstein–Barr virus associated the follicular germinal center B cell lymphomas. J. Cancer Res. Ther. 15, 350–357 (2019).
344. Thomas, R. M. et al. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models. Carcinogenesis 39, 1068–1078 (2018).
345. Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10, 10–27 (2019).
346. Ciocan, D. et al. Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis. Sci. Rep. 8, 4822 (2018).
347. Chen, J., Domingue, J. C. & Sears, C. L. Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin. Immunol. 32, 25–34 (2017).
348. Guo, Y., Liu, W. & Wu, J. Helicobacter pylori infection and pancreatic cancer risk: a meta-analysis. J. Cancer Res. Ther. 12, C229–c232 (2016).
349. Huang, J. et al. Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: a nested case–control study. Int. J. Cancer 140, 1727–1735 (2017).
350. Wei, M. Y. et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol. Cancer 18, 97 (2019).
351. Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science (New York, NY) 357, 1156–1160 (2017).
352. Pushalkar, S. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403–416 (2018).
353. Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e712 (2019).
354. Mitsuhashi, K. et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6, 7209–7220 (2015).
355. Maekawa, T. et al. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem. Biophys. Res. Commun. 506, 962–969 (2018).
356. Serra, N. et al. Bactibilia in women affected with diseases of the biliary tract and pancreas. A STROBE guidelines-adherent cross-sectional study in Southern Italy. J. Med. Microbiol. 67, 1090–1095 (2018).
357. Gaiser, R. A. et al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut https://doi.org/10.1136/gutjnl-2018-317458 (2019).
358. Fan, X. et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67, 120–127 (2018).
359. Ochi, A. et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209, 1671–1687 (2012).
360. Akshintala, V. S., Talukdar, R., Singh, V. K. & Goggins, M. The gut microbiome in pancreatic disease. Clin. Gastroenterol. Hepatol. 17, 290–295 (2019).
361. Sethi, V. et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155, 33–37.e36 (2018).
362. Vogel, A. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv238–iv255 (2018).
363. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
364. Ren, Z. et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68, 1014–1023 (2019).
365. Islami, F. et al. Disparities in liver cancer occurrence in the United States by race/ ethnicity and state. CA Cancer J. Clin. 67, 273–289 (2017).
366. Gerbes, A. et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 67, 380–388 (2018).
367. Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319–1329 (2019).
368. Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
369. Kim, D. et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 69, 1064–1074 (2019).
370. Munoz, L. et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. Hepatology https://doi.org/10.1002/hep.30349 (2018).
371. Iida, N. et al. Overuse of antianaerobic drug is associated with poor post-chemotherapy prognosis of patients with hepatocellular carcinoma. Int. J. Cancer https://doi.org/10.1002/ijc.32339 (2019).
372. Grat, M. et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transpl. Proc. 48, 1687–1691 (2016).
373. Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107–120 (2019).
374. Ni, J. et al. Analysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma. Front. Microbiol. 10, 1458 (2019).
375. Pinero, F. et al. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Ann. Hepatol. 18, 480–487 (2019).
376. Liu, Q. et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 11, 1 (2019).
377. Huang, Y. et al. Identification of Helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J. Clin. Pathol. 57, 1273–1277 (2004).
378. Rocha, M. et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 54, 396–401 (2005).
379. Kruttgen, A. et al. Study on the association of Helicobacter species with viral hepatitis-induced hepatocellular carcinoma. Gut Microbes 3, 228–233 (2012).
380. Yang, J., Ji, S., Zhang, Y. & Wang, J. Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue. Singap. Med. J. 54, 451–457 (2013).
381. Pere-Vedrenne, C. et al. The cytolethal distending toxin subunit CdtB of Helicobacter induces a Th17-related and antimicrobial signature in intestinal and hepatic cells in vitro. J. Infect. Dis. 213, 1979–1989 (2016).
382. Pere-Vedrenne, C. et al. The cytolethal distending toxin subunit CdtB of Helicobacter hepaticus promotes senescence and endoreplication in xenograft mouse models of hepatic and intestinal cell lines. Front. Cell Infect. Microbiol. 7, 268 (2017).
383. Fox, J. G. et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59, 88–97 (2010).
384. Zhang, H. L. et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol. 57, 803–812 (2012).
385. Mohamadkhani, A. On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B. Cancer Med. https://doi.org/10.1002/cam4.1550 (2018).
386. Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504–516 (2012).
387. Yu, L. X. et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322–1333 (2010).
388. Yu, L. X. & Schwabe, R. F. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat. Rev. Gastroenterol. Hepatol. 14, 527–539 (2017).
389. Wu, M. Y., Yiang, G. T., Cheng, P. W., Chu, P. Y. & Li, C. J. Molecular targets in hepatocarcinogenesis and implications for therapy. J. Clin. Med. 7, 213–239 (2018).
390. Yin, Z. et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J. Cell. Biochem. 119, 9419–9432 (2018).
391. Weng, Z. et al. Anti-Inflammatory activity of dehydroandrographolide by TLR4/ NF-kappaB signaling pathway inhibition in bile duct-ligated mice. Cell Physiol. Biochem. 49, 1083–1096 (2018).
392. Loo, T. M. et al. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity. Cancer Disco. 7, 522–538 (2017).
393. Yamada, S. et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 9, 9925–9939 (2018).
394. Schramm, C. Bile acids, the microbiome, immunity, and liver tumors. N. Engl. J. Med. 379, 888–890 (2018).
395. Li, R. et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. https://doi.org/10.1038/s41418-019-0312-y (2019).
396. Li, Q. et al. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. J. Exp. Clin. Cancer Res. 38, 303 (2019).
397. Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. https://doi.org/10.3322/caac.21565 (2019).
398. Wender, R. C., Brawley, O. W., Fedewa, S. A., Gansler, T. & Smith, R. A. A blueprint for cancer screening and early detection: advancing screening's contribution to cancer control. CA Cancer J. Clin. 69, 50–79 (2019).
399. Allemani, C. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018).
400. Wu, L. et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat. Genet. 50, 968–978 (2018).
401. Knight, J. A. et al. Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE study. Int. J. Cancer 141, 916–924 (2017).
402. Sung, H. et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J. Clin. 69, 88–112 (2019).
403. Goedert, J. J. et al. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br. J. Cancer 118, 471–479 (2018).
404. Goedert, J. J. et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case–control pilot study. J. Natl. Cancer Inst. 107, https://doi.org/10.1093/jnci/djv147 (2015).
405. Zhu, J. et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 6, 136 (2018).
406. Luu, T. H. et al. Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. Nutr. Cancer 69, 267–275 (2017).
407. Velicer, C. M. et al. Antibiotic use in relation to the risk of breast cancer. JAMA 291, 827–835 (2004).
408. Tamim, H. M., Hanley, J. A., Hajeer, A. H., Boivin, J. F. & Collet, J. P. Risk of breast cancer in relation to antibiotic use. Pharmacoepidemiol. Drug Saf. 17, 144–150 (2008).
409. Satram-Hoang, S. et al. A pilot study of male breast cancer in the Veterans Affairs healthcare system. J. Environ. Pathol. Toxicol. Oncol. 29, 235–244 (2010).
410. Velicer, C. M., Heckbert, S. R., Rutter, C., Lampe, J. W. & Malone, K. Association between antibiotic use prior to breast cancer diagnosis and breast tumour characteristics (United States). Cancer Causes Control 17, 307–313 (2006).
411. Friedman, G. D. et al. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol. Biomark. Prev. 15, 2102–2106 (2006).
412. Kirkup, B. et al. Perturbation of the gut microbiota by antibiotics results in accelerated breast tumour growth and metabolic dysregulation. bioRXiv https://doi.org/10.1101/553602 (2019).
413. Buchta Rosean, C. et al. Pre-existing commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 79, 3662–3675 (2019).
414. Lakritz, J. R. et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget 6, 9387–9396 (2015).
415. Rao, V. P. et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 66, 7395–7400 (2006).
416. Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 27–40 (2015).
417. Patel, D. A. et al. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 174, 443–452 (2019).
418. Moon, G., Noh, H., Cho, I. J., Lee, J. I. & Han, A. Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence. Breast Cancer (Tokyo, Japan) https://doi.org/10.1007/s12282-019-00994-z (2019).
419. Erdman, S. E. & Poutahidis, T. Gut bacteria and cancer. Biochim. Biophys. Acta 1856, 86–90 (2015).
420. Lakritz, J. R. et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int. J. Cancer 135, 529–540 (2014).
421. Kovacs, T. et al. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci. Rep. 9, 1300 (2019).
422. Miko, E. et al. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochim. Biophys. Acta Bioenerg. 1859, 958–974 (2018).
423. Tang, X. et al. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res. 16, 415 (2014).
424. Swales, K. E. et al. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66, 10120–10126 (2006).
425. Miko, E. et al. Microbiome–microbial metabolome–cancer cell interactions in breast cancer-familiar, but unexplored. Cells 8, https://doi.org/10.3390/cells8040293 (2019).
426. Salimi, V. et al. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment. Lipids Health Dis. 16, 208 (2017).
427. Thirunavukkarasan, M. et al. Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells. PLoS ONE 12, e0186334 (2017).
428. Plottel, C. S. & Blaser, M. J. Microbiome and malignancy. Cell Host Microbe 10, 324–335 (2011).
429. Tao, J. et al. Targeting gut microbiota with dietary components on cancer: effects and potential mechanisms of action. Crit. Rev. Food Sci. Nutr. https://doi. org/10.1080/10408398.2018.1555789, 1–13 (2019).
430. Chen, F. P. & Chien, M. H. Effects of phytoestrogens on the activity and growth of primary breast cancer cells ex vivo. J. Obstet. Gynaecol. Res. 45, 1352–1362 (2019).
431. Basu, P. & Maier, C. Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomed. Pharmacother. 107, 1648–1666 (2018).
432. Rodriguez-Garcia, C., Sanchez-Quesada, C., Toledo, E., Delgado-Rodriguez, M. & Gaforio, J. J. Naturally lignan-rich foods: a dietary tool for health promotion? Molecules 24, https://doi.org/10.3390/molecules24050917 (2019).
433. Mali, A. V., Padhye, S. B., Anant, S., Hegde, M. V. & Kadam, S. S. Anticancer and antimetastatic potential of enterolactone: clinical, preclinical and mechanistic perspectives. Eur. J. Pharm. 852, 107–124 (2019).
434. Bowers, L. W. et al. The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFkappaB signaling, and inhibits mammary tumor growth. Breast Cancer Res. Treat. 173, 545–557 (2019).
435. Mali, A. V., Joshi, A. A., Hegde, M. V. & Kadam, S. S. Enterolactone modulates the ERK/NF-kappaB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-beta-induced epithelial–mesenchymal transition. Cancer Biol. Med. 15, 137–156 (2018).
436. Di, Y., De Silva, F., Krol, E. S. & Alcorn, J. Flaxseed lignans enhance the cytotoxicity of chemotherapeutic agents against breast cancer cell lines MDA-MB-231 and SKBR3. Nutr. Cancer 70, 306–315 (2018).
437. Liss, M. A. et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur. Urol. 74, 575–582 (2018).
438. Sfanos, K. S. et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 21, 539–548 (2018).
439. Golombos, D. M. et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 111, 122–128 (2018).
440. Fenner, A. Unearthing roles for the gut microbiome. Nat. Rev. Urol. 15, 589 (2018).
441. Zhang, W. Q. et al. Alterations of fecal bacterial communities in patients with lung cancer. Am. J. Transl. Res. 10, 3171–3185 (2018).
442. Liu, Y. et al. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am. J. Cancer Res. 8, 1775–1787 (2018).
443. Lee, S. H. et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 102, 89–95 (2016).
444. Jin, C. et al. Commensal microbiota promote lung cancer development via gammadelta T cells. Cell 176, 998–1013.e1016 (2019).
445. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
446. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science (New York, NY) 359, 1350–1355 (2018).
447. Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
448. Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity 49, 1148–1161.e1147 (2018).
449. Pai, C. S. et al. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J. Clin. Investig. 129, 349–363 (2019).
450. Du, X. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 28, 416–432 (2018).
451. Du, X. et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res. 28, 433–447 (2018).
452. Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233–1238 (2019).
453. Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).
454. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
455. Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
456. Zheng, Y. et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J. Immunother. Cancer 7, 193 (2019).
457. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, NY) 359, 91–97 (2018).
458. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, NY) 359, 97–103 (2018).
459. Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC. J. Thorac. Oncol. https://doi.org/10.1016/j.jtho.2019.04.007 (2019).
460. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (New York, NY) 359, 104–108 (2018).
461. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (New York, NY) 350, 1084–1089 (2015).
462. Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (New York, NY) 350, 1079–1084 (2015).
463. Sen, S., Carmagnani Pestana, R., Hess, K., Viola, G. M. & Subbiah, V. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Ann. Oncol. 29, 2396–2398 (2018).
464. Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848–855 (2017).
465. Botticelli, A. et al. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget 8, 8890–8899 (2017).
466. Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V. & Wargo, J. A. The microbiome, cancer, and cancer therapy. Nat. Med. 25, 377–388 (2019).
467. Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).
468. Vangay, P. et al. US immigration westernizes the human gut microbiome. Cell 175, 962–972.e910 (2018).
469. Deschasaux, M. et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat. Med. 24, 1526–1531 (2018).
470. Wang, Y. et al. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock. Science (New York, NY) 357, 912–916 (2017).
471. Allen, J. M. et al. Exercise training-induced modification of the gut microbiota persists after microbiota colonization and attenuates the response to chemically-induced colitis in gnotobiotic mice. Gut Microbes 9, 115–130 (2018).
472. Allen, J. M. et al. Exercise alters gut microbiota composition and function in lean and obese humans. Med. Sci. Sports Exerc. 50, 747–757 (2018).
473. Munukka, E. et al. Six-week endurance exercise alters gut metagenome that is not reflected in systemic metabolism in over-weight women. Front. Microbiol. 9, 2323 (2018).
474. Gao, X. et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc. Natl. Acad. Sci. USA 115, E2960–e2969 (2018).
475. Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
476. Bajaj, J. S. et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am. J. Gastroenterol. 113, 1177–1186 (2018).
477. Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919–1929 (2018).
478. Gong, S. et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J. Hepatol. 69, 51–59 (2018).
479. Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e1321 (2018).
480. Thaiss, C. A. et al. Microbiota diurnal rhythmicity programs host transcriptome oscillations. Cell 167, 1495–1510.e1412 (2016).
481. Gharaibeh, R. Z. & Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut https://doi.org/10.1136/gutjnl-2018-317220 (2018).
482. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
483. Chen, D., Wu, J., Jin, D., Wang, B. & Cao, H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int. J. Cancer https://doi. org/10.1002/ijc.32003 (2018).
484. Wang, J. W. et al. Initial experience of fecal microbiota transplantation in gastrointestinal disease: a case series. Kaohsiung J. Med. Sci. https://doi.org/10.1002/kjm2.12094 (2019).
485. Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).
486. Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156–164 (2019).
487. Ianiro, G. et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of ndrome. Aliment Pharmacol. Ther. https://doi.org/10.1111/apt.15330 (2019).
488. Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic ence-phalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology https://doi.org/10.1002/hep.30690 (2019).
489. Kang, D. W. et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5, 10 (2017).
490. McQuade, J. L., Daniel, C. R., Helmink, B. A. & Wargo, J. A. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 20, e77–e91 (2019).
491. Ooijevaar, R. E., Terveer, E. M., Verspaget, H. W., Kuijper, E. J. & Keller, J. J. Clinical application and potential of fecal microbiota transplantation. Annu. Rev. Med. 70, 335–351 (2019).
492. Langdon, A., Crook, N. & Dantas, G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8, 39 (2016).
493. Olesen, S. W., Leier, M. M., Alm, E. J. & Kahn, S. A. Searching for superstool: maximizing the therapeutic potential of FMT. Nat. Rev. Gastroenterol. Hepatol. 15, 387–388 (2018).
494. Youngster, I. et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312, 1772–1778 (2014).
495. Russell, G. H. et al. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 58, 588–592 (2014).
496. Alang, N. & Kelly, C. R. Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2, ofv004 (2015).
497. Hohmann, E. L., Ananthakrishnan, A. N. & Deshpande, V. Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N. Engl. J. Med. 371, 668–675 (2014).
498. Schwartz, M., Gluck, M. & Koon, S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am. J. Gastroenterol. 108, 1367 (2013).
499. Wong, S. H. et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153, 1621–1633.e1626 (2017).
500. Dailey, F. E., Turse, E. P., Daglilar, E. & Tahan, V. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr. Opin. Pharm. 49, 29–33 (2019).
501. Elinav, E., Garrett, W. S., Trinchieri, G. & Wargo, J. The cancer microbiome. Nat. Rev. Cancer 19, 371–376 (2019).
502. de Groot, P. et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut https://doi.org/10.1136/gutjnl-2019-318320 (2019).
503. Hildebrand, F. et al. Antibiotics-induced monodominance of a novel gut bacterial order. Gut https://doi.org/10.1136/gutjnl-2018-317715 (2019).
504. Jiang, Z. D. et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection—fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharm. Ther. 45, 899–908 (2017).
505. Papanicolas, L. E. et al. Bacterial viability in faecal transplants: Which bacteria survive? EBioMedicine 41, 509–516 (2019).
506. Xu, D. et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol. 114, 1043–1050 (2019).
507. Kao, D. et al. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318, 1985–1993 (2017).
508. Valdes, A. M., Walter, J., Segal, E. & Spector, T. D. Role of the gut microbiota in nutrition and health. BMJ 361, k2179 (2018).
509. Panigrahi, P. et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 548, 407–412 (2017).
510. Sung, V. et al. Lactobacillus reuteri to treat infant colic: a meta-analysis. Pediatrics 141, https://doi.org/10.1542/peds.2017-1811 (2018).
511. Johnston, B. C., Goldenberg, J. Z. & Parkin, P. C. Probiotics and the prevention of antibiotic-associated diarrhea in infants and children. JAMA 316,1484–1485 (2016).
512. Goldenberg, J. Z., Mertz, D. & Johnston, B. C. Probiotics to prevent Clostridium difficile infection in patients receiving antibiotics. JAMA 320, 499–500 (2018).
513. Piewngam, P. et al. Pathogen elimination by probiotic Bacillus via signalling interference. Nature 562, 532–537 (2018).
514. Isabella, V. M. et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018).
515. Li, J. et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. USA 113, E1306–E1315 (2016).
516. Shi, L. et al. Combination therapy of TGF-beta blockade and commensal-derived probiotics provides enhanced antitumor immune response and tumor suppression. Theranostics 9, 4115–4129 (2019).
517. Yamamoto, M. L. et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 73, 4222–4232 (2013).
518. Bindels, L. B. et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 10, 1456–1470 (2016).
519. Le Noci, V. et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. Cell Rep. 24, 3528–3538 (2018).
520. Aso, Y. et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur. Urol. 27, 104–109 (1995).
521. Shin, W. & Kim, H. J. Intestinal barrier dysfunction orchestrates the onset of inflammatory host–microbiome cross-talk in a human gut inflammation-on-a-chip. Proc. Natl. Acad. Sci. USA 115, E10539–E10547 (2018).
522. Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e1416 (2018).
523. Maldonado-Gomez, M. X. et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20, 515–526 (2016).
524. Shepherd, E. S., DeLoache, W. C., Pruss, K. M., Whitaker, W. R. & Sonnenburg, J. L. An exclusive metabolic niche enables strain engraftment in the gut microbiota. Nature 557, 434–438 (2018).
525. Baxter, N. T. et al. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. mBio, 10 https://doi.org/10.1128/mBio.02566-18 (2019).
526. Gurry, T. et al. Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. Sci. Rep. 8, 12699 (2018).
527. Matt, S. M. et al. Butyrate and dietary soluble fiber improve neuroinflammation associated with aging in mice. Front. Immunol. 9, 1832 (2018).
528. Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl. Med. 11, https://doi.org/10.1126/scitranslmed.aau7975 (2019).
529. Reardon, S. Genetically modified bacteria enlisted in fight against disease. Nature 558, 497–498 (2018).
530. Stanislawski, M. A., Dabelea, D., Lange, L. A., Wagner, B. D. & Lozupone, C. A. Gut microbiota phenotypes of obesity. NPJ Biofilms Microbiomes 5, 18 (2019).
531. Zhang, Y. et al. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res. 145, 163–168 (2018).
532. Olson, C. A. et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173, 1728–1741.e1713 (2018).
533. Hampton, T. Gut microbes may account for the anti-seizure effects of the ketogenic diet. JAMA 320, 1307 (2018).
534. Miranda, P. M. et al. High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production. Microbiome 6, 57 (2018).
535. Ma, Y. et al. Dietary patterns and risk of hepatocellular carcinoma among U.S. men and women. Hepatology https://doi.org/10.1002/hep.30362 (2018).
536. Zmora, N., Soffer, E. & Elinav, E. Transforming medicine with the microbiome. Sci. Transl. Med. 11, https://doi.org/10.1126/scitranslmed.aaw1815 (2019).
537. Gentile, C. L. & Weir, T. L. The gut microbiota at the intersection of diet and human health. Science (New York, NY) 362, 776–780 (2018).
538. Chambers, E. S. et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut 68, 1430–1438 (2019).
539. Bindels, L. B. et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107, 1337–1344 (2012).